Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Last Updated: November 17, 2019

DrugPatentWatch Database Preview

NPLATE Drug Profile

See Plans and Pricing

« Back to Dashboard

Summary for Tradename: NPLATE

Patents:	20
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for NPLATE

Recent Clinical Trials for NPLATE

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Amgen	Phase 3
University Children's Hospital Basel	Phase 4
University Hospital, Basel, Switzerland	Phase 4

See all NPLATE clinical trials

Pharmacology for NPLATE

Mechanism of Action	Thrombopoietin Receptor Agonists
Physiological Effect	Increased Megakaryocyte Maturation Increased Platelet Production

Company Disclosures: US Patents for NPLATE

These patents were extracted from company disclosures

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Amgen	NPLATE	romiplostim	INJECTABLE; SUBCUTANEOUS	125268	001	2008-08-22	Start Trial	Amgen Inc. (Thousand Oaks, CA)	2018-10-23	RX		company
Amgen	NPLATE	romiplostim	INJECTABLE; SUBCUTANEOUS	125268	001	2008-08-22	Start Trial	Amgen Inc. (Thousand Oaks, CA)	2018-10-23	RX		company
Amgen	NPLATE	romiplostim	INJECTABLE; SUBCUTANEOUS	125268	001	2008-08-22	Start Trial	Amgen Inc. (Thousand Oaks, CA)	2018-10-23	RX		company
Amgen	NPLATE	romiplostim	INJECTABLE; SUBCUTANEOUS	125268	001	2008-08-22	Start Trial	Amgen Inc. (Thousand Oaks, CA)	2018-10-23	RX		company
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Number	>Approval Date	>Patent No.	>Assignee	>Estimated Patent Expiration	>Status	>Orphan	>Source

Patent Text Search: US Patents for NPLATE

These patents were identified by searching patent claims

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Amgen	NPLATE	romiplostim	INJECTABLE; SUBCUTANEOUS	125268	001	2008-08-22	Start Trial	SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL)	2033-03-11	RX		search
Amgen	NPLATE	romiplostim	INJECTABLE; SUBCUTANEOUS	125268	001	2008-08-22	Start Trial	University of the Sciences of Philadelphia (Philadelphia, PA)	2034-11-21	RX		search
Amgen	NPLATE	romiplostim	INJECTABLE; SUBCUTANEOUS	125268	001	2008-08-22	Start Trial	AMGEN INC. (Thousand Oaks, CA)	2039-02-26	RX		search
Amgen	NPLATE	romiplostim	INJECTABLE; SUBCUTANEOUS	125268	001	2008-08-22	Start Trial	BAYER INTELLECTUAL PROPERTY GMBH (Monheim, DE)	2031-04-05	RX		search
Amgen	NPLATE	romiplostim	INJECTABLE; SUBCUTANEOUS	125268	001	2008-08-22	Start Trial	CORNELL UNIVERSITY (Ithaca, NY)	2035-10-02	RX		search
Amgen	NPLATE	romiplostim	INJECTABLE; SUBCUTANEOUS	125268	001	2008-08-22	Start Trial	Glactone Pharma Development AB (Helsingborg, SE)	2030-07-19	RX		search
Amgen	NPLATE	romiplostim	INJECTABLE; SUBCUTANEOUS	125268	001	2008-08-22	Start Trial	Ohio University (Athens, OH)	2030-03-24	RX		search
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Number	>Approval Date	>Patent No.	>Assignee	>Estimated Patent Expiration	>Status	>Orphan	>Source

International Patents for NPLATE

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Japan	2007084557	Start Trial
Japan	2003533187	Start Trial
Bulgaria	105401	Start Trial
Hungary	0104327	Start Trial
Australia	2004200691	Start Trial
Japan	2002536960	Start Trial
Hungary	0203506	Start Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for NPLATE

Subscribe to access the full database, or Start Trial
Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
122009000039	Germany	Start Trial	PRODUCT NAME: ROMIPLOSTIM; REGISTRATION NO/DATE: EU/1/08/497/001-002 20090204
PA2009006,C1124961	Lithuania	Start Trial	PRODUCT NAME: ROMIPLOSTIMUM; REGISTRATION NO/DATE: EU/1/08/497/001-002 20090204
PA2009006	Lithuania	Start Trial	PRODUCT NAME: ROMIPLOSTIMUM; REGISTRATION NO/DATE: EU/1/08/497/001-002 20090204
346	Finland	Start Trial
C01124961/01	Switzerland	Start Trial	FORMER REPRESENTATIVE: BOHEST AG, CH
2009/022	Ireland	Start Trial	PRODUCT NAME: ROMIPLOSTIM; REGISTRATION NO/DATE: EU/1/08/497/001-002 20090204
300398	Netherlands	Start Trial	300398, 20191022, EXPIRES: 20240203
>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca

Merck

Harvard Business School

McKesson

Moodys

McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.